A Study Of PF-06263507 In Patients With Advanced Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Neoplasms|Carcinoma, Non Small Cell Lung|Breast Neoplasms|Ovarian Neoplasms
Interventions: DRUG: PF-06263507|DRUG: PF-06263507
Sponsor: Pfizer